Φορτώνει......
Challenge of immune-mediated adverse reactions in the emergency department
Multiple drugs of a new class of cancer treatments called immune checkpoint inhibitors, which work by enabling the immune system to attack tumour cells, have been approved for a variety of indications in recent years. Immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 and programmed death-...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Emerg Med J |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BMJ Publishing Group
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6582806/ https://ncbi.nlm.nih.gov/pubmed/31113799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/emermed-2018-208206 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|